FDA 483 - Fitbit LLC - May 22, 2023

An FDA inspection of Fitbit LLC in San Francisco, CA, revealed significant deficiencies in a non-significant risk device study. The firm failed to maintain IRB approval, keep accurate and complete records of adverse device effects, and ensure investigator compliance. These issues indicate serious non-compliance with regulations for investigational device exemptions.